In a crowded, genericized field like epilepsy, a new drug's success depends not just on achieving statistical significance but on the magnitude of its effect. For Xenon, the key question is whether its drug can match or exceed the ~34% placebo-adjusted seizure reduction shown by competitor Xcopri, setting a high bar for commercial relevance.

While Eli Lilly's Retrutide showed headline-grabbing weight loss, a concerning 18% of patients discontinued one study due to side effects. A subsequent trial showing a much lower discontinuation rate (5%) was seen as a major win, indicating patient tolerability is now as critical as raw efficacy for commercial success.

Compass Pathways' stock surged despite its depression drug showing a smaller-than-expected effect. Investors grade on a curve, recognizing the difficulty of psychiatric trials and prioritizing statistically significant results over the magnitude of benefit, given the commercial success of similar drugs.

As multiple obesity drugs offer similar high efficacy, the crucial market differentiator will shift to tolerability. Patients are more likely to notice and care about debilitating side effects like nausea than a 1-2% difference in weight loss. A "kinder, gentler" drug could capture significant market share from more potent competitors.

Neurocrine's strategy with its M4 agonist hinges on achieving superior safety and tolerability through high selectivity. The company believes that for chronic psychiatric disorders, long-term patient adherence—driven by fewer side effects—is a more critical factor for commercial success than marginal gains in efficacy.

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

Despite showing massive weight loss, new obesity drugs from Eli Lilly and others have high discontinuation rates due to side effects. This suggests the industry's singular focus on efficacy may be hitting diminishing returns, opening a new competitive front based on better patient tolerance and adherence.

Interpreting early-stage, open-label epilepsy trial data requires nuance. A high seizure reduction percentage confirms a drug is likely effective, but investors should expect a significant drop in that effect size in a placebo-controlled study. The key takeaway is mechanistic validation, not the specific number.

Ron Cooper highlights a key disconnect: Wall Street values the highest efficacy ("more is better"), but community physicians, who treat most patients, weigh three factors equally: efficacy, tolerability, and ease of administration. A drug that seamlessly integrates into their practice flow can win significant market share without best-in-class efficacy.